Progressis / Vaccines / Swine / Ceva United Kingdom

Porcine respiratory and reproductive syndrome (PRRS) is difficult to control and there is emerging circulation of variable field strains worldwide. PRRS still is a huge economic concern, with economic losses varying from € 59 to € 379 per sow during an outbreak. The yearly cost of infected farms is around € 100 per sow (1). PRRS impairs immunity after infection resulting in a slow and incomplete immune response, which leaves the animal more susceptible to other diseases. Impaired reproductive and respiratory performance is also a major impact of PRRS.

Progressis® incorporates a new concept, the Dual Technology Prime Boost, resulting in boosted immunity in a PRRS-positive environment. Progressis® results in reduction of reproductive disorders caused by PRRS in a contaminated environment, including reduced early farrowings, reduction of stillbirths (1) and reduction of viraemic piglets at weaning (2). Progressis® induces cell mediated immunity and humoral immunity resulting in a broad and effective immune response (3,4,5).

Reynaud et al., Zootechnical efficacy of vaccination of gilts and sows with an inactivated PRRS vaccine in a contaminated environment. IPVS 2000: 601
Joisel et al., PRRS: vaccination with a killed vaccine - field experience. The Pig Journal 2001, 48: 120-137
Kim et al., ELISA antibody response after vaccination with an inactivated EU-typed PRRS vaccine in a Korean farm. APVS 2015: 83
Kim et al., Serum neutralization (SN) antibody response in sows and transfer to piglets after sow vaccination with an inactivated EU-typed PRRS vaccine in a Korean Farm. APVS 2015: 84
Juillard et al., Ex-vivo stimulation with different PRRSV strains for cellular mediated immunity monitoring of PROGRESSIS vaccinated pigs. ISERPD 2007: 144

Progressis Emulsion for injection for pigs (sows and gilts). Active ingredient: Progressis® contains inactivated Porcine Reproductive and Respiratory Syndrome (PRRS) virus. Please refer to the product packaging and leaflets for information about side effects, precautions and warnings. Legal Category: UK POM- V IE: POM. Further information is available on the SPC.